Emily Voigt, Ph.D.

Director, RNA Platform

Dr. Emily Voigt heads AAHI’s RNA vaccine development efforts, from early-stage preclinical development and testing through preparation for Phase I clinical trials. A trained vaccine immunologist, she serves as Key Scientist on a major NIH vaccine development contract targeting yellow fever and Zika viruses using AAHI's NLC-delivered RNA platform, with plans to enter Phase I clinical testing by 2023. Additionally, Dr. Voigt serves as principal investigator on a Department of Defense-funded grant to further enhance AAHI’s RNA vaccine platform with the use of genetic adjuvants, and contributes vaccine immunology expertise to AAHI’s adjuvant development efforts.

Dr. Voigt was previously a Research Fellow in the Mayo Clinic’s Vaccine Research Group, where her research focused on studies of human immune responses to viral vaccines. She earned her Ph.D. from the University of Wisconsin-Madison studying the interactions between replicating RNA viruses and the innate immune responses of the cells they infect.